Skip to main content

Advertisement

SpringerLink
Log in

MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis

  • Review Article
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Epidemiological studies have investigated the association between MDM2 promoter SNP 309 (T/G) and endometrial cancer susceptibility. However, the results are still controversial. To obtain a more precise estimate of the relationship, we conducted a meta-analysis of 1,001 cases and 1,889 controls from 6 published case–control studies (one of five articles contains two studies) to estimate the effect of SNP309 on endometrial cancer risk. The strength of association between MDM2 SNP309 and endometrial cancer susceptibility was assessed by calculating pooled odds ratios (ORs) with 95% confidence intervals (CIs). When all the eligible studies were pooled in the meta-analysis, we found that elevated endometrial cancer risk was significantly associated with GG variant genotype, however, heterozygous genotype TG seemed to be only a minor modifier on endometrial cancer risk (for GG vs. TT, OR = 1.54, 95% CI = 1.21–1.95, P = 0.0004; for TG vs. TT, OR = 0.96, 95% CI = 0.81–1.14, P = 0.66; for dominant model, OR = 1.09, 95% CI = 0.93–1.29, P = 0.29; for recessive model, OR = 1.65, 95% CI = 1.33–2.04, P < 0.00001). Overall, the meta-analysis suggested that the GG genotype of MDM2 SNP309 was significantly associated with the increased endometrial cancer risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Bakkum-Gamez JN, Gonzalez-Bosquet J, Laack NN, Mariani A, Dowdy SC. Current issues in the management of endometrial cancer. Mayo Clin Proc. 2008;83(1):97–112.

    Article  PubMed  Google Scholar 

  2. Olson SH, Bandera EV, Orlow I. Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review. Am J Epidemiol. 2007;165(3):235–45.

    Article  PubMed  Google Scholar 

  3. Ghasemi N, Karimi-Zarchi M, Mortazavi-Zadeh MR, Atash-Afza A. Evaluation of the frequency of TP53 gene codon 72 polymorphisms in Iranian patients with endometrial cancer. Cancer Genet Cytogenet. 2010;196(2):167–70.

    Article  PubMed  CAS  Google Scholar 

  4. Goodfellow PJ, Buttin BM, Herzog TJ, Rader JS, Gibb RK, Swisher E, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci USA. 2003;100(10):5908–13.

    Article  PubMed  CAS  Google Scholar 

  5. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358(6381):80–3.

    Article  PubMed  CAS  Google Scholar 

  6. Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets. 2005;5(1):27–41.

    Article  PubMed  CAS  Google Scholar 

  7. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26(15):3453–9.

    Article  PubMed  CAS  Google Scholar 

  8. Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev. 2002;12(1):53–9.

    Article  PubMed  CAS  Google Scholar 

  9. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591–602.

    Article  PubMed  CAS  Google Scholar 

  10. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005;65(13):5481–4.

    Article  PubMed  CAS  Google Scholar 

  11. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 2006;66(10):5104–10.

    Article  PubMed  CAS  Google Scholar 

  12. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer. 2006;119(3):718–21.

    Article  PubMed  CAS  Google Scholar 

  13. Sanchez-Carbayo M, Socci ND, Kirchoff T, Erill N, Offit K, Bochner BH, et al. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clin Cancer Res. 2007;13(11):3215–20.

    Article  PubMed  CAS  Google Scholar 

  14. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387(6630):296–9.

    Article  PubMed  CAS  Google Scholar 

  15. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst. 2006;98(4):285–8.

    Article  PubMed  CAS  Google Scholar 

  16. Lum SS, Chua HW, Li H, Li WF, Rao N, Wei J, et al. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis. 2008;29(4):754–61.

    Article  PubMed  CAS  Google Scholar 

  17. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Jarvinen HJ, et al. The MDM2 promoter polymorphism SNP309T–>G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet. 2005;42(9):694–8.

    Article  PubMed  CAS  Google Scholar 

  18. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet. 2006;43(6):531–3.

    Article  PubMed  CAS  Google Scholar 

  19. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res. 2005;65(20):9582–7.

    Article  PubMed  CAS  Google Scholar 

  20. Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, et al. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol. 2009;113(1):109–14.

    Article  PubMed  CAS  Google Scholar 

  21. Terry K, McGrath M, Lee IM, Buring J, De Vivo I. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(4):983–6.

    Article  PubMed  CAS  Google Scholar 

  22. Nunobiki O, Ueda M, Yamamoto M, Toji E, Sato N, Izuma S, et al. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum Cell. 2009;22(4):101–6.

    Article  PubMed  Google Scholar 

  23. Ueda M, Yamamoto M, Nunobiki O, Toji E, Sato N, Izuma S, et al. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell. 2009;22(2):49–54.

    Article  PubMed  Google Scholar 

  24. Walsh CS, Miller CW, Karlan BY, Koeffler HP. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol. 2007;104(3):660–4.

    Article  PubMed  CAS  Google Scholar 

  25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.

    PubMed  CAS  Google Scholar 

  26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

    Article  PubMed  Google Scholar 

  27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

    Article  PubMed  CAS  Google Scholar 

  28. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.

    PubMed  CAS  Google Scholar 

  29. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science. 2001;291(5507):1304–51.

    Article  PubMed  CAS  Google Scholar 

  30. Chen J, Wu X, Lin J, Levine AJ. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol. 1996;16(5):2445–52.

    PubMed  CAS  Google Scholar 

  31. Cheah PL, Looi LM. p53: an overview of over two decades of study. Malays J Path. 2001;23(1):9–16.

    CAS  Google Scholar 

  32. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387(6630):299–303.

    Article  PubMed  CAS  Google Scholar 

  33. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24(17):2899–908.

    Article  PubMed  CAS  Google Scholar 

  34. Bouska A, Eischen CM. Mdm2 affects genome stability independent of p53. Cancer Res. 2009;69(5):1697–701.

    Article  PubMed  CAS  Google Scholar 

  35. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem. 2005;280(29):26776–87.

    Article  PubMed  CAS  Google Scholar 

  36. Harris SL, Gil G, Robins H, Hu W, Hirshfield K, Bond E, et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci USA. 2005;102(45):16297–302.

    Article  PubMed  CAS  Google Scholar 

  37. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, Tollenaar RA, et al. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res. 2007;67(19):9584–90.

    Article  PubMed  CAS  Google Scholar 

  38. Gudas JM, Nguyen H, Klein RC, Katayose D, Seth P, Cowan KH. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin Cancer Res. 1995;1(1):71–80.

    PubMed  CAS  Google Scholar 

  39. Phelps M, Darley M, Primrose JN, Blaydes JP. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res. 2003;63(10):2616–23.

    PubMed  CAS  Google Scholar 

  40. Bueso-Ramos CE, Manshouri T, Haidar MA, Yang Y, McCown P, Ordonez N, et al. Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res Treat. 1996;37(2):179–88.

    Article  PubMed  CAS  Google Scholar 

  41. Okumura N, Saji S, Eguchi H, Nakashima S, Saji S, Hayashi S. Distinct promoter usage of mdm2 gene in human breast cancer. Oncol Rep. 2002;9(3):557–63.

    PubMed  CAS  Google Scholar 

  42. Schultz JR, Petz LN, Nardulli AM. Cell- and ligand-specific regulation of promoters containing activator protein-1 and Sp1 sites by estrogen receptors alpha and beta. J Biol Chem. 2005;280(1):347–54.

    PubMed  CAS  Google Scholar 

  43. Safe S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm. 2001;62:231–52.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors of this study declare there are no applicable conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong, People’s Republic of China

    Yan Li, Linjuan Huang & Beihua Kong

  2. Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, People’s Republic of China

    Hongjin Zhao

  3. Department of Gynecology Oncology, Shandong Cancer Hospital Shandong Academy of Medical Science, Jinan, Shandong, People’s Republic of China

    Li Sun

  4. Department of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong, People’s Republic of China

    Qifeng Yang

Authors
  1. Yan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hongjin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Linjuan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qifeng Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Beihua Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Beihua Kong.

Additional information

Y. Li and H. Zhao contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, Y., Zhao, H., Sun, L. et al. MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis. Human Cell 24, 57–64 (2011). https://doi.org/10.1007/s13577-011-0013-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-011-0013-4

Keywords

Search

Navigation